Table 1.
Baseline characteristics of patients from bimekizumab (BE OPTIMAL/BE COMPLETE/BE VITAL) and guselkumab (DISCOVER-2/COSMOS) trials before matching
| bDMARD-naïve | TNFi-IR | ||||
|---|---|---|---|---|---|
| Mean (SD) unless stated | BE OPTIMAL | DISCOVER-2 (Q4W) | DISCOVER-2 (Q8W) | BE COMPLETE/BE VITAL | COSMOS |
| N = 431 | N = 245 | N = 248 | N = 267 | N = 189 | |
| Age, years | 49 (13) | 46 (12) | 45 (12) | 50 (12) | 49 (12) |
| Male, % | 47 | 58 | 52 | 49 | 46 |
| Time since diagnosis, years | 6.0 (7.3) | 5.5 (5.9) | 5.1 (5.5) | 9.6 (9.9) | 8.3 (7.8) |
| MTX use, % | 59 | 69 | 69 | 45 | 56 |
| SJC (of 66 joints) | 9.0 (6.2) | 12.9 (7.8) | 11.7 (6.8) | 9.7 (7.5) | 10.0 (7.0) |
| TJC (of 68 joints) | 16.8 (11.8) | 22.4 (13.5) | 19.8 (11.9) | 18.4 (13.5) | 21.0 (13.0) |
| HAQ-DI score | 0.82 (0.59) | 1.2 (0.6) | 1.3 (0.6) | 0.97 (0.59) | 1.3 (0.6) |
| BSA ≥ 3%, % | 50 | 75 | 71 | 66 | 70 |
bDMARD biologic disease-modifying antirheumatic drug, BSA body surface area, HAQ-DI Health Assessment Questionnaire Disability Index, MTX methotrexate, Q4W every 4 weeks, Q8W every 8 weeks, SD standard deviation, SJC swollen joint count, TJC tender joint count, TNFi-IR tumor necrosis factor inhibitor-inadequate response or intolerant